$0.96
1.88% today
Nasdaq, Feb 05, 04:12 pm CET
ISIN
US1850631045
Symbol
CLSD
Sector
Industry

Clearside Biomedical, Inc. Stock price

$0.98
-0.01 1.42% 1M
-0.11 10.24% 6M
+0.03 2.99% YTD
-0.41 29.61% 1Y
-0.81 45.34% 3Y
-2.34 70.53% 5Y
-6.27 86.50% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.04 4.09%
ISIN
US1850631045
Symbol
CLSD
Sector
Industry

Key metrics

Market capitalization $74.21m
Enterprise Value $100.59m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 13.06
P/S ratio (TTM) P/S ratio 9.64
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 248.39%
Revenue (TTM) Revenue $7.70m
EBIT (operating result TTM) EBIT $-24.65m
Free Cash Flow (TTM) Free Cash Flow $-19.60m
Cash position $23.59m
EPS (TTM) EPS $-0.45
P/E forward negative
P/S forward 44.30
EV/Sales forward 60.04
Short interest 2.50%
Show more

Is Clearside Biomedical, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Clearside Biomedical, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Clearside Biomedical, Inc. forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Clearside Biomedical, Inc. forecast:

Buy
100%

Financial data from Clearside Biomedical, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
7.70 7.70
248% 248%
100%
- Direct Costs 0.17 0.17
73% 73%
2%
7.54 7.54
377% 377%
98%
- Selling and Administrative Expenses 12 12
4% 4%
150%
- Research and Development Expense 20 20
5% 5%
266%
-24 -24
18% 18%
-318%
- Depreciation and Amortization 0.17 0.17
143% 143%
2%
EBIT (Operating Income) EBIT -25 -25
18% 18%
-320%
Net Profit -32 -32
15% 15%
-414%

In millions USD.

Don't miss a Thing! We will send you all news about Clearside Biomedical, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Clearside Biomedical, Inc. Stock News

Neutral
GlobeNewsWire
one day ago
ALPHARETTA, Ga., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today George Lasezkay, PharmD, JD, President and Chief Executive Officer, and Victor Chong, MD, MBA, Chief Medical Officer and EVP, Head of Research and Develo...
Neutral
GlobeNewsWire
8 days ago
- Upcoming Presentations at Angiogenesis and Macula Society Conferences to Feature  CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial -
Neutral
GlobeNewsWire
14 days ago
- ARCATUS ® , Branded as XIPERE ® in the U.S., is the First Globally Approved Suprachoroidal Therapy -
More Clearside Biomedical, Inc. News

Company Profile

Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Head office United States
CEO George Lasezkay
Employees 30
Founded 2011
Website www.clearsidebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today